Oppenheimer Asset Management Inc. increased its position in Inogen Inc (NASDAQ:INGN) by 2,688.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,402 shares of the medical technology company’s stock after acquiring an additional 3,280 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Inogen were worth $227,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in INGN. Advisor Group Inc. grew its holdings in Inogen by 71.4% during the 2nd quarter. Advisor Group Inc. now owns 461 shares of the medical technology company’s stock valued at $31,000 after buying an additional 192 shares in the last quarter. Hanson McClain Inc. purchased a new stake in Inogen during the 1st quarter valued at approximately $50,000. TRUE Private Wealth Advisors purchased a new stake in Inogen during the 2nd quarter valued at approximately $66,000. Steward Partners Investment Advisory LLC purchased a new stake in Inogen during the 2nd quarter valued at approximately $119,000. Finally, Victory Capital Management Inc. purchased a new stake in Inogen during the 1st quarter valued at approximately $163,000.

In other Inogen news, Director Heath Lukatch bought 2,000 shares of the firm’s stock in a transaction dated Thursday, August 15th. The stock was acquired at an average cost of $43.01 per share, for a total transaction of $86,020.00. Following the completion of the transaction, the director now owns 5,481 shares in the company, valued at $235,737.81. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, Director Loren L. Mcfarland bought 1,000 shares of the firm’s stock in a transaction dated Wednesday, September 4th. The shares were acquired at an average price of $42.93 per share, with a total value of $42,930.00. Following the completion of the transaction, the director now owns 4,481 shares of the company’s stock, valued at approximately $192,369.33. The disclosure for this purchase can be found here. 4.54% of the stock is owned by company insiders.

A number of brokerages have issued reports on INGN. BidaskClub lowered shares of Inogen from a “sell” rating to a “strong sell” rating in a report on Friday, August 9th. KeyCorp reaffirmed a “hold” rating on shares of Inogen in a report on Wednesday, August 7th. Stifel Nicolaus lowered shares of Inogen from a “buy” rating to a “hold” rating and cut their price objective for the company from $85.00 to $48.00 in a report on Wednesday, August 7th. Needham & Company LLC downgraded Inogen from a “buy” rating to a “hold” rating in a research report on Wednesday, August 7th. Finally, Leerink Swann downgraded Inogen from an “outperform” rating to a “market perform” rating in a research report on Thursday, August 8th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the stock. Inogen presently has an average rating of “Hold” and a consensus price target of $82.17.

INGN traded up $2.82 during trading on Friday, reaching $49.90. The company had a trading volume of 52,915 shares, compared to its average volume of 455,786. The stock has a market cap of $1.02 billion, a P/E ratio of 21.64, a PEG ratio of 2.76 and a beta of 1.50. The business has a 50 day simple moving average of $48.80 and a 200-day simple moving average of $72.28. Inogen Inc has a 52 week low of $41.19 and a 52 week high of $287.79. The company has a quick ratio of 6.82, a current ratio of 7.35 and a debt-to-equity ratio of 0.01.

Inogen (NASDAQ:INGN) last issued its quarterly earnings results on Wednesday, August 7th. The medical technology company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). The company had revenue of $101.10 million during the quarter, compared to the consensus estimate of $106.88 million. Inogen had a return on equity of 13.34% and a net margin of 11.24%. The firm’s quarterly revenue was up 3.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.65 earnings per share. As a group, equities research analysts expect that Inogen Inc will post 1.09 EPS for the current fiscal year.

Inogen Profile

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Featured Story: How to invest in blue-chip stocks

Want to see what other hedge funds are holding INGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inogen Inc (NASDAQ:INGN).

Institutional Ownership by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.